investor login

contact

team

dedicated funds

news

 portfolio

 

AN2 Therapeutics (“AN2”) is a biopharmaceutical company focused on developing novel medicines for patients with rare, orphan infectious diseases that represent significant unmet needs. Founded by a team of experienced industry leaders in infectious diseases drug research and development, we strive to provide patients with treatments that will restore their health and enable them to live productive lives.

AN2 is a mission-driven company. We have a passion for improving global public health and a vision to accelerate development of novel medicines to treat serious infectious diseases and save lives worldwide.

IPO in March 2022 (NASDAQ: ANTX)

VISIT WEBSITE

Bio Tech, HVP VI, Public

back to portfolio

contact

© hatteras venture partners | all rights reserved | terms + privacy | site credit

 team

 portfolio

news

home

Hatteras Venture Partners is a venture capital firm that builds transformational companies in areas of health innovation.

dedicated funds

contact

 team

dedicated funds

news

home

 portfolio